Innovative delivery of siRNA to solid tumors by super carbonate apatite

36Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

RNA interference (RNAi) technology is currently being tested in clinical trials for a limited number of diseases. However, systemic delivery of small interfering RNA (siRNA) to solid tumors has not yet been achieved in clinics. Here, we introduce an in vivo pH-sensitive delivery system for siRNA using super carbonate apatite (sCA) nanoparticles, which is the smallest class of nanocarrier. These carriers consist simply of inorganic ions and accumulate specifically in tumors, yet they cause no serious adverse events in mice and monkeys. Intravenously administered sCA-siRNA abundantly accumulated in the cytoplasm of tumor cells at 4 h, indicating quick achievement of endosomal escape. sCA-survivin-siRNA induced apoptosis in HT29 tumors and significantly inhibited in vivo tumor growth of HCT116, to a greater extent than two other in vivo delivery reagents. With innovative in vivo delivery efficiency, sCA could be a useful nanoparticle for the therapy of solid tumors.

Cite

CITATION STYLE

APA

Wu, X., Yamamoto, H., Nakanishi, H., Yamamoto, Y., Inoue, A., Tei, M., … Mori, M. (2015). Innovative delivery of siRNA to solid tumors by super carbonate apatite. PLoS ONE, 10(3). https://doi.org/10.1371/journal.pone.0116022

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free